What Is Ecnoglutide?

1. What Is Ecnoglutide?

Ecnoglutide is a GLP-1 receptor agonist injection developed by Sciwind Biosciences. Sciwind announced that China’s National Medical Products Administration approved ecnoglutide injection for glycemic control in adults with type 2 diabetes on January 30, 2026, and for chronic weight management in Chinese adults with overweight or obesity on March 6, 2026.

The older code name is XW003. ClinicalTrials.gov uses XW003 in the SLIMMER trial record, while Sciwind’s 2026 approval releases and journal articles use ecnoglutide. That is a naming shift, not two different drugs.

Ecnoglutide naming and classification:

A China NMPA approval is not the same thing as a U.S. FDA-approved label, an EMA authorization, or global availability.

2. What Does cAMP-Biased GLP-1 Mean?

Nature Communications describes ecnoglutide as a cyclic adenosine monophosphate, or cAMP, biased GLP-1 analogue. The paper says the molecule contains an alanine-to-valine substitution at position 8 and an 18-C fatty acid conjugation at lysine 30.

In practical terms, ecnoglutide is designed to favor cAMP signaling at the GLP-1 receptor while reducing beta-arrestin recruitment. Sciwind describes that as a biased GLP-1 receptor agonism mechanism. This specific mechanism of action describes how the drug interacts with the receptor, but does not inherently equate to clinical superiority over other GLP-1 drugs.

Key terminology:

For broader class background, see What Is a GLP-1?.

3. Where Is Ecnoglutide Approved?

Sciwind announced two China NMPA approvals in 2026: adult type 2 diabetes on January 30 and chronic weight management in Chinese adults with overweight or obesity on March 6.

The FDA’s substance record lists ecnoglutide, XW003, and XW-003 as names or mappings for the same substance, but notes that UNII availability does not imply regulatory review or approval.

As of May 6, 2026, ecnoglutide has China NMPA approval but does not have a U.S. FDA approval label.

4. What Did SLIMMER Report for Weight Management?

SLIMMER was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial in Chinese adults with overweight or obesity and without diabetes. ClinicalTrials.gov lists it as NCT05813795, with 664 enrolled participants and once-weekly subcutaneous XW003 or placebo for 48 weeks.

The Lancet Diabetes & Endocrinology paper reported week 40 co-primary endpoint results. At week 40, least-squares mean bodyweight change was minus 9.1% with 1.2 mg ecnoglutide, minus 10.9% with 1.8 mg, minus 13.2% with 2.4 mg, and plus 0.1% with placebo.

Sciwind’s March 2026 approval release focused on week 48. It reported 15.4% mean weight reduction and 15.1% placebo-adjusted weight reduction in the 2.4 mg group, plus 92.8% of participants reaching at least 5% weight loss.

The trial also reported that treatment-emergent adverse events were common across groups, with mild-to-moderate gastrointestinal events listed as the most common category. Ten ecnoglutide-treated participants discontinued treatment because of adverse events in the Lancet report.

5. What Did EECOH-1 Report for Type 2 Diabetes?

EECOH-1 was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial of once-weekly ecnoglutide in adults with type 2 diabetes. Nature Communications says the study tested 0.6 mg and 1.2 mg ecnoglutide versus placebo, with the primary endpoint at week 24.

The trial randomized 211 participants. At week 24, the least-squares mean A1C change was minus 1.96% with 0.6 mg ecnoglutide, minus 2.43% with 1.2 mg, and minus 0.87% with placebo. Nature Communications reported treatment differences versus placebo of minus 1.09% and minus 1.56% for the two ecnoglutide doses.

The same paper reported bodyweight changes. At week 24, least-squares mean bodyweight change was minus 3.04 kg with 0.6 mg, minus 3.21 kg with 1.2 mg, and minus 1.45 kg with placebo.

6. What Did EECOH-2 Compare?

EECOH-2 compared ecnoglutide with dulaglutide in adults with type 2 diabetes whose glucose remained elevated on metformin monotherapy. PubMed describes it as a 52-week, open-label, active-controlled, randomized phase 3 trial at 52 hospitals in China.

The primary endpoint was A1C change at week 32. PubMed reports that estimated treatment differences versus dulaglutide were minus 0.26% with ecnoglutide 0.6 mg and minus 0.24% with ecnoglutide 1.2 mg, with the 1.2 mg dose meeting the listed superiority test.

It is important to note that EECOH-2 had a specific population, dose protocol, comparator, geography, and open-label design, meaning results may not generalize across all settings.

For context on the dulaglutide comparator, see What Is Trulicity? and What Is Dulaglutide?.

7. How Is Ecnoglutide Different From Semaglutide or Tirzepatide?

Ecnoglutide, semaglutide, and tirzepatide are different active ingredients. Ecnoglutide is described as a cAMP-biased GLP-1 receptor agonist. Semaglutide is a GLP-1 receptor agonist active ingredient used in brands such as Ozempic, Wegovy, and Rybelsus. Tirzepatide is a GIP and GLP-1 receptor agonist active ingredient used in brands such as Mounjaro and Zepbound.

8. What Facts Matter Most?

Ecnoglutide is currently a China-approved drug, which is a distinct regulatory status from FDA or EMA approval.

Ecnoglutide summary:

For GLP-1 class background, see What Is a GLP-1?. For better-known names, start with What Is Semaglutide?, What Is Dulaglutide?, and What Is Tirzepatide?.

9. What Is Ecnoglutide FAQ

• What is ecnoglutide in simple terms?

  Ecnoglutide is a GLP-1 receptor agonist injection also known as XW003. Sciwind describes it as a cAMP-biased GLP-1 receptor agonist, and the China NMPA approved it for adult type 2 diabetes and chronic weight management in Chinese adults with overweight or obesity.

• Is ecnoglutide the same as XW003?

  Yes. XW003 is the development code used for ecnoglutide. ClinicalTrials.gov lists XW003 in the SLIMMER study, while later publications and releases use the ecnoglutide name.

• Is ecnoglutide FDA-approved in the United States?

  No. Ecnoglutide currently has China NMPA approval, not a U.S. FDA drug label. The FDA's substance record lists ecnoglutide and XW003 as synonyms, but notes that UNII availability does not imply regulatory review or approval.

• What does cAMP-biased GLP-1 mean?

  It means the molecule is described as favoring cyclic adenosine monophosphate, or cAMP, signaling at the GLP-1 receptor while reducing beta-arrestin recruitment.

• What did the SLIMMER trial report?

  The SLIMMER phase 3 trial studied Chinese adults with overweight or obesity without diabetes. At 48 weeks, Sciwind reported a 15.4% mean weight reduction and 15.1% placebo-adjusted weight reduction in the 2.4 mg ecnoglutide group.

10. Sources